WolframESamlowskiMD

Oncology • Las Vegas, NV

Clinical Professor of Medicine at University of Nevada School of Medicine.

Join to view full profile

Dr. Samlowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Samlowski's full profile

Already have an account?

Office
9280 W Sunset Rd
Ste 100
Las Vegas, NV 89148
Phone+1 702-952-1251

Fax+1 702-952-1242

Education & Training

University of Utah HealthFellowship, Hematology and Medical Oncology, 1981 - 1984
Wayne State University School of MedicineResidency, Internal Medicine, 1978 - 1981
Ohio State University College of MedicineClass of 1978

Certifications & Licensure

UT State Medical License 1981 - 2026
NV State Medical License 2007 - 2025
MI State Medical License 1979 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Vegas Seven Castle Connolly, 2014
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Desert Companion Castle Connolly, 2011
Join now to see all

Clinical Trials

S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Start of enrollment: 1999 Nov 01
Completed
Phase 2
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2009 Apr 01
Terminated
Phase 1
5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates Start of enrollment: 2009 Apr 01
Terminated
Phase 1
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers Start of enrollment: 2016 Jun 01
Completed
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma Start of enrollment: 2012 Aug 01
Unknown status
Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice.
Claire Victoria Ong, Wolfram Samlowski
Journal of Neuro-Oncology. 2025-02-11
Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy.
Chalette Lambert-Swainston, Wolfram Samlowski, Brandon Reynolds, Amin Hedayat
Frontiers in Oncology. 2025-01-01
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC mel...
Wolfram Samlowski, Michelle A Silver, Andriana Hohlbauch, Shujing Zhang, Mizuho Fukunaga-Kalabis
Melanoma Research. 2024-08-01

Press Mentions

Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021
Health Care Quarterly’s 2020 Top DoctorsAugust 20th, 2020

Grant Support

Epigenetic Potentiation Of Interferon Using DecitabineNational Cancer Institute2007–2008
Phase I Trial Of Php With High-Dose IL-2National Cancer Institute2006
Phase I Trial Of Php With High-Dose IL-2National Cancer Institute2005–2006
Southwest Oncology Group (UTAH)National Cancer Institute1993–2003
Toxicity Of Continuous Infusion N Acetyl Cysteine With High Dose IL2National Center For Research Resources1998–2002
Nitric Oxide As A Tumor DefenseNational Cancer Institute1997–1999
Toxicity Of Continuous Infusion N-Acetyl Cysteine With High Dose IL-2National Center For Research Resources1995–1997
Phase II Trial--Il-2 Treatment Of Relapsed Or Refractory ANLLNational Center For Research Resources1996
FACS Vantage Cell SorterNational Center For Research Resources1995
Use Of Sulfhydryl Compounds To Increase IL-2 ActivityNational Cancer Institute1992–1994
Endothelial Cell Toxicity Of Marrow Ablative AgentsNational Cancer Institute1988–1992

Professional Memberships

American Society of Clinical Oncology - ASCO
Member